Thrive Wealth Management LLC Has $1.52 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Thrive Wealth Management LLC grew its holdings in Danaher Co. (NYSE:DHR) by 4.9% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 6,070 shares of the conglomerate’s stock after buying an additional 283 shares during the quarter. Thrive Wealth Management LLC’s holdings in Danaher were worth $1,516,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP grew its position in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after buying an additional 2,998,161 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Danaher by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after acquiring an additional 1,619,586 shares in the last quarter. Capital International Investors increased its position in shares of Danaher by 9.1% during the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after purchasing an additional 1,334,781 shares during the last quarter. Norges Bank acquired a new position in shares of Danaher during the 4th quarter worth approximately $1,752,382,000. Finally, Franklin Resources Inc. increased its holdings in shares of Danaher by 6.4% during the 4th quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock worth $1,531,510,000 after acquiring an additional 395,498 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 0.1 %

NYSE DHR traded up $0.27 during trading hours on Friday, hitting $252.03. 146,349 shares of the company’s stock were exchanged, compared to its average volume of 2,813,437. The stock has a 50-day simple moving average of $255.36 and a 200 day simple moving average of $246.19. The firm has a market cap of $186.68 billion, a price-to-earnings ratio of 42.68, a PEG ratio of 3.88 and a beta of 0.85. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $269.11.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.36 earnings per share. On average, equities analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research reports. Robert W. Baird upped their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Jefferies Financial Group initiated coverage on Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. TD Cowen upped their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and increased their target price for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, Barclays increased their target price on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average target price of $269.29.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now directly owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Danaher news, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold a total of 148,783 shares of company stock worth $37,536,717 over the last ninety days. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.